CD4 and systemic lupus erythematosus: One patient with SLE (P8) was refractory to baricitinib, albeit IL-6 induction was approximately 2% in CD4+ and CD8+ T cells and 0.2% in CD11b+ cells, suggesting the activation in other inflammatory pathways involved in the pathomechanisms of SLE in that patient.